Back to ALCView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Target Indication
Neovascular Age-Related Macular Degeneration
Clinical Trial
NCT02307682Last updated: 12/23/2025
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA2/13/2020
Beovu
Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Ofloxacin otic solutionPhase 3
Acute Otitis Media
Difluprednate 0.05% ophthalmic emulsionPhase 3
Endogenous Anterior Uveitis
Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Phase 3
Allergic Conjunctivitis
AL-4943A ophthalmic solutionPhase 3
Allergic Conjunctivitis
Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solutionPhase 3
Glaucoma, Open-angle
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts